On March 4, 2025, Cereno Scientific held a webcast in connection with the press release published on February 25, 2025, where additional data from the Phase IIa trial with CS1 were shared showing encouraging signs of reverse vascular remodeling effects of CS1.
Company executives shared the Phase IIa trial data with a presentation followed by a Q&A session. The webcast was hosted by BioStock.
0:00 Introduction
1:00 Cereno Scientific in short
5:34 HDACi platform, PAH and CS1
13:52 Phase IIa results and next step
28:13 Future outlook
31:26 Q&A - analysts
46:47 Q&A viewer's questions
51:42 Final words
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: https://www.linkedin.com/company/biostock
Facebook: https://www.facebook.com/biostock.se
https://www.biostock.se/
#BioStock #LifeScience #CerenoScientific
About BioStock
BioStock is Scandinavia's leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office and tv-studio is found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies.